Loading stock data…
$7.23+0.06 (+0.84%)
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
Cumberland Pharmaceuticals Inc. in the Healthcare sector is trading at $7.23 with a market capitalization of $108M. The stock is currently 22% below its 52-week high of $9.28, remaining 56.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $166,458↓ | $9.13M↓ | $13.68M↑ | $8.29M↑ | $380,797 |
| Gross Profit | — | $7.20M↓ | $11.44M↑ | $7.30M↓ | $8.83M |
| Operating Income | -$3.16M↓ | -$3.13M↓ | -$1.37M↑ | -$1.97M↑ | -$3.12M |
| Net Income | -$4.28M↓ | -$3.29M↓ | -$1.41M↑ | -$1.94M↓ | -$740,740 |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Cal...